Advanced Chemotherapy Technologies
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
A developer of devices intended to deliver chemotherapy into tumors with poor blood supply.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Advanced Chemotherapy Technologies is founded in North Carolina as a spin-out of the University of North Carolina at Chapel Hill, based on technology developed by professors Joseph DeSimone and Jen Jen Yeh: an implantable iontophoretic drug delivery system designed to deliver chemotherapy directly to solid tumors such as pancreatic cancer with laser-like precision. The company closes prior seed financing rounds in 2017.
- Series A and grants
In February 2021, the company announces a $2.5 million Series A investment from Spectrum Financial to accelerate clinical trials of its lead product for pancreatic tumors; it also receives a $4 million National Institutes of Health grant.
- Renamed and acquired
The company, by now renamed Focal Medical, is acquired by Continuity Biosciences, LLC, announced June 4, 2025. Its lead product candidate, an iontophoresis device delivering gemcitabine to pancreatic tumors, has been cleared by the FDA through an Investigational New Drug application, with Phase 1b clinical trials expected later in 2025.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.